Background: Difficulties in inhibition and self-monitoring are early features of incipient Alzheimer's disease and may manifest as susceptibility to proactive semantic interference. However, due to limitations of traditional memory assessment paradigms, recovery from interference effects following repeated learning opportunities has not been explored.
Objective: This study employed a novel computerized list learning test consisting of repeated learning trials to assess recovery from proactive and retroactive semantic interference.
Design: The design was cross-sectional.
Setting: Participants were recruited from the community as part of a longitudinal study on normal and abnormal aging.
Participants: The sample consisted of 46 cognitively normal individuals and 30 participants with amnestic mild cognitive impairment.
Measurements: Participants were administered the Cognitive Stress Test and traditional neuropsychological measures. Step-wise logistic regression was applied to determine which Cognitive Stress Test measures best discriminated between diagnostic groups. This was followed by receiver operating characteristic analyses.
Results: Cued A3 recall, Cued B3 recall and Cued B2 intrusions were all independent predictors of diagnostic status. The overall predictive utility of the model yielded 75.9% sensitivity, 91.1% specificity, and an overall correct classification rate of 85.1%. When these variables were jointly entered into receiver operating characteristic analyses, the area under the curve was .923 (p<.001).
Conclusions: This novel paradigm's use of repeated learning trials offers a unique opportunity to assess recovery from proactive and retroactive semantic interference. Participants with mild cognitive impairment exhibited a continued failure to recover from proactive interference that could not be explained by mere learning deficits.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500547 | PMC |
http://dx.doi.org/10.14283/jpad.2021.3 | DOI Listing |
Aging Brain
October 2024
Department of Psychiatry and Behavioral Sciences, Stanford University, USA.
Affective symptoms (i.e., depression, anxiety, and apathy) are the most prevalent subsyndrome of neuropsychiatric symptoms (NPS) in preclinical dementia, such as amnestic mild cognitive impairment (aMCI), and remain a challenge to understand and treat.
View Article and Find Full Text PDFIntroduction: Hippocampal hyperactivity is a hallmark of prodromal Alzheimer's disease (AD) that predicts progression in patients with amnestic mild cognitive impairment (aMCI). AGB101 is an extended-release formulation of levetiracetam in the dose range previously demonstrated to normalize hippocampal activity and improve cognitive performance in aMCI. The HOPE4MCI study was a 78-week trial to assess the progression of MCI due to AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Nuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven, Belgium.
Introduction: The longitudinal progression of synaptic loss in Alzheimer's disease (AD) and how it is affected by tau pathology remains poorly understood.
Methods: Thirty patients with amnestic mild cognitive impairment (aMCI) and 26 healthy controls underwent cognitive evaluations and tau, synaptic vesicle protein 2A (SV2A), and amyloid positron emission tomography. Twenty-one aMCI underwent 2-year follow-up (FU) investigations.
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn
December 2024
Rotman Research Institute, Baycrest Academy for Research and Education, Toronto, Ontario, Canada.
Individuals with amnestic mild cognitive impairment (aMCI), a prodromal stage of Alzheimer's disease and other dementias, show inhibition deficits in addition to episodic memory. How the latent processes of selective attention (i.e.
View Article and Find Full Text PDFFront Aging Neurosci
December 2024
Department of Neurology, Affiliated Hospital of Xiangnan University, Chenzhou, China.
Background: Brain has been shown to undergo progressive atrophy in patients with Alzheimer's disease (AD); however, more evidence is needed to elucidate how the brain structure changes during the progression to AD. Here, we observed differences in the cerebral structure among patients with amnestic mild cognitive impairment (aMCI) and patients with AD.
Methods: A total of 46 participants were selected and divided into AD, aMCI, and healthy control (HC) groups.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!